Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doparkin
- Development stage
- Phase 4
- Lead developer
- General Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doparkin is an oral fixed-dose combination of levodopa, a dopamine precursor, and carbidopa, a peripheral dopa decarboxylase (DDC) inhibitor, developed and marketed by General Pharmaceuticals for the treatment of Parkinson's disease and parkinsonian syndromes. Levodopa crosses the blood-brain barrier and is converted into dopamine in the brain, replenishing depleted striatal dopamine levels to alleviate motor symptoms such as rigidity, bradykinesia, and tremors. Because levodopa is rapidly metabolized in peripheral tissues, carbidopa is co-administered to inhibit peripheral decarboxylation. Since carbidopa does not cross the blood-brain barrier, it increases the bioavailability of levodopa to the central nervous system while reducing peripheral dopaminergic side effects like nausea and vomiting.
- Brand names
- Doparkin
- Other names
- carbidopa + levodopacarbidopa/levodopalevodopa + carbidopalevodopa/carbidopa
02
Targets
DDC (Aromatic L-amino acid decarboxylase)
Beyond the preview
Go deeper on Doparkin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doparkin.